Welcome to our dedicated page for Dentsply Sirona news (Ticker: XRAY), a resource for investors and traders seeking the latest updates and insights on Dentsply Sirona stock.
DENTSPLY SIRONA Inc. (Nasdaq: XRAY) regularly issues news and updates that shed light on its role as the world’s largest diversified manufacturer of professional dental products and technologies. Company press releases cover topics such as strategic partnerships, leadership changes, financial results and portfolio decisions, giving investors and dental professionals insight into how the business is evolving.
Recent news has highlighted Dentsply Sirona’s focus on connected dentistry and technology-enabled solutions. The company has announced expanded and renewed distribution partnerships in the United States that provide access to its dental technology portfolio, including systems and imaging solutions referenced in those agreements. These announcements emphasize integrated ecosystems that connect devices, software and services from scanning through design and manufacturing workflows.
News items also address corporate strategy and performance, including quarterly financial results and the introduction of a Return-to-Growth action plan. In these updates, Dentsply Sirona outlines priorities such as putting customers at the center, strengthening the U.S. business, and evolving operations to support innovation and training. Leadership appointments in commercial, finance and regional roles are frequently reported, reflecting the company’s efforts to align its organization with these priorities.
Other press releases describe decisions about the Wellspect Healthcare business, dividend declarations, participation in investor conferences and the conclusion of an SEC Division of Enforcement investigation without enforcement action. Together, these news items provide a detailed view of how Dentsply Sirona manages its portfolio, governance and capital allocation. Readers interested in XRAY can use this news feed to follow developments in connected dentistry, strategic partnerships, governance actions and financial communications from the company.
Dentsply Sirona (Nasdaq: XRAY) announced on August 15, 2022, it remains non-compliant with Nasdaq Listing Rules, failing to file its Quarterly Reports on Form 10-Q for the first two quarters of 2022. Despite an earlier extension to file by August 14, the Company could not meet this deadline. An internal investigation regarding financial reporting matters is ongoing, complicating the filing process. Nasdaq may grant additional time to regain compliance, potentially extending the deadline to November 7, 2022. The notices received do not impact the current listing status of XRAY shares.
Dentsply Sirona (Nasdaq: XRAY) announced preliminary results for Q2 2022, expecting net sales over $1,005 million and adjusted EPS at or above $0.60. Despite year-over-year sales decline due to foreign exchange impacts, organic sales grew, driven by strong demand in Europe and recent product launches. An ongoing internal investigation into financial matters may delay the filing of its quarterly report. The company has declared a quarterly dividend of $0.125 per share, payable on October 14, 2022. Nasdaq compliance issues are also addressed, with an extension granted for filing the required reports.
DENTSPLY SIRONA Inc. (Nasdaq: XRAY) announced a quarterly cash dividend of $0.125 per share, indicating an annual rate of $0.50. This dividend is scheduled for payment on July 8, 2022, to shareholders of record as of June 24, 2022. Dentsply Sirona is recognized as the world’s largest manufacturer of professional dental products, providing innovative solutions that enhance patient care. The company has a strong portfolio of products and brands, reinforcing its commitment to the dental industry.
Dentsply Sirona (Nasdaq: XRAY) received a notification from Nasdaq on May 12, 2022, indicating non-compliance with listing rules due to the failure to file its Quarterly Report on Form 10-Q for the period ended March 31, 2022. The Company has 60 days to address this deficiency or submit a compliance plan. This notice does not immediately affect the stock's listing, and the Company aims to file the missing report as soon as possible. An investigation regarding the accounting of sales incentives is ongoing, which may have contributed to the delay.
Dentsply Sirona (Nasdaq: XRAY) reported Q1 2022 net sales of $965 million, a decrease of 6.1% from $1,027 million in Q1 2021. EPS dropped to $0.30, down 43.8%, while adjusted EPS decreased to $0.52 from $0.72. Operating income fell 39.5% to $93 million. Despite these declines, operating cash flow improved to $93 million. The company updated its FY2022 outlook, projecting organic sales growth of 2% to 3% and adjusted EPS between $2.35 and $2.55. Challenges stemmed from macroeconomic headwinds and weaker U.S. performance.
Summary not available.
Dentsply Sirona launched DS Core, a cloud-based platform enhancing digital dentistry, in collaboration with Google Cloud. The integrated system simplifies workflows, allows remote collaboration, and supports compliance with patient data regulations. Additionally, two new services, DS Core Create and DS Core Care, aim to optimize dental design and equipment support. The Primeprint Solution, an automated 3D printing system, was also introduced, promising efficiency and safety in dental practices. These innovations position Dentsply Sirona at the forefront of digital dentistry.
Dentsply Sirona (Nasdaq: XRAY) announced a revised date for its first quarter 2022 earnings conference call, now scheduled for May 10, 2022, at 8:30 am ET, moving from the previously set date of May 5. The call will be accessible via a live webcast on the Investors section of the company's website. A presentation related to the call will be published online, and a replay will be available for a week post-call. As the largest manufacturer of dental products, Dentsply Sirona continues to focus on innovation and effective solutions for patient care.
WellAir announced the appointment of Kari Dixon as President and CEO, effective immediately, succeeding Todd M. Pope, who will serve as Vice-Chair of the Board. Dixon, previously WellAir's CFO, possesses extensive experience in capital markets and financial planning, having worked with Dentsply Sirona and Form Technologies. Todd highlighted WellAir's advancements, including the launch of the FDA cleared Defend 400 air cleaning solution. Dixon aims to drive growth in the indoor air quality sector, emphasizing its significance in community wellness.
Dentsply Sirona has appointed John Groetelaars as Interim CEO following the termination of Don Casey. The Board is actively seeking a new CEO with a focus on driving operational excellence. Additionally, Barbara Bodem has been named Interim CFO to ensure a smooth transition after the departure of Jorge Gomez. Dentsply Sirona anticipates first quarter net sales of approximately $965 million, indicating a 1.4% decline year-over-year, affected by weaker U.S. sales and supply chain challenges. Further financial details will be disclosed on May 5, 2022.